Soluble human urokinase receptor is composed of two active units

被引:23
作者
Higazi, AAR
Mazar, A
Wang, JY
Quan, N
Griffin, R
Reilly, R
Henkin, J
Cines, DB
机构
[1] UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104
[2] ABBOTT LABS,ABBOTT PK,IL 60064
关键词
D O I
10.1074/jbc.272.8.5348
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mechanism by which single-chain urokinase (scuPA) binds to its receptor (uPAR) is incompletely understood, We report that a fragment comprising the first domain of recombinant soluble uPAR (sDI) as well as a fragment comprising the remaining domains (sDII-DIII) competes with the binding of recombinant full-length soluble uPAR (suPAR) to scuPA with an IC50 = 253 nM and an IC50 = 1569, respectively, sDII-III binds directly to scuPA with K-d = 238 nM. Binding of scuPA to each fragment also induces the expression of plasminogen activator activity. sDI and sDII-DIII (200 nM each) induced activity equal to 66 and 36% of the maximum activity induced by full-length suPAR (5 nM), respectively, Each fragment also stimulates the binding of scuPA to cells lacking endogenous uPAR, Although scuPA binds to sDI and to sDII-DIII through its amino-terminal fragment, the fragments act synergistically to inhibit the binding of suPAR and to stimulate plasminogen activator activity, Furthermore, sDII-DIII retards the velocity and alters the pattern of cleavage of sDI by chymotrypsin, These results suggest that binding of scuPA to more than one epitope in suPAR is required for its optimal activation and association with cell membranes.
引用
收藏
页码:5348 / 5353
页数:6
相关论文
共 25 条
[1]  
APPELLA E, 1987, J BIOL CHEM, V262, P4437
[2]  
BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865
[3]  
BEHRENDT N, 1991, J BIOL CHEM, V266, P7842
[4]   THE UROKINASE RECEPTOR - PROTEIN-STRUCTURE AND ROLE IN PLASMINOGEN ACTIVATION AND CANCER INVASION [J].
DANO, K ;
BEHRENDT, N ;
BRUNNER, N ;
ELLIS, V ;
PLOUG, M ;
PYKE, C .
FIBRINOLYSIS, 1994, 8 :189-203
[5]   Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans - A murine transgenic model [J].
Gyetko, MR ;
Chen, GH ;
McDonald, RA ;
Goodman, R ;
Huffnagle, GB ;
Wilkinson, CC ;
Fuller, JA ;
Toews, GB .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (08) :1818-1826
[6]   THE UROKINASE RECEPTOR IS REQUIRED FOR HUMAN MONOCYTE CHEMOTAXIS IN-VITRO [J].
GYETKO, MR ;
TODD, RF ;
WILKINSON, CC ;
SITRIN, RG .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (04) :1380-1387
[7]   ENHANCEMENT OF THE ENZYMATIC-ACTIVITY OF SINGLE-CHAIN UROKINASE PLASMINOGEN-ACTIVATOR BY SOLUBLE UROKINASE RECEPTOR [J].
HIGAZI, AA ;
COHEN, RL ;
HENKIN, J ;
KNISS, D ;
SCHWARTZ, BS ;
CINES, DB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (29) :17375-17380
[8]   Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins [J].
Higazi, AAR ;
Upson, RH ;
Cohen, RL ;
Manuppello, J ;
Bognacki, J ;
Henkin, J ;
McCrae, KR ;
Kounnas, MZ ;
Strickland, DK ;
Preissner, KT ;
Lawler, J ;
Cines, DB .
BLOOD, 1996, 88 (02) :542-551
[9]   Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1 [J].
Higazi, AAR ;
Mazar, A ;
Wang, JY ;
Reilly, R ;
Henkin, J ;
Kniss, D ;
Cines, D .
BLOOD, 1996, 87 (09) :3545-3549
[10]   Unesterified long chain fatty acids inhibit the binding of single chain urokinase to the urokinase receptor [J].
Higazi, AAR ;
Aceto, JF ;
Kniss, D ;
Upson, R ;
Cohen, R ;
Dichek, DA ;
Cines, DB .
BIOCHEMISTRY, 1996, 35 (21) :6884-6890